WO2007108009A1 - Procede de purification du topiramate - Google Patents
Procede de purification du topiramate Download PDFInfo
- Publication number
- WO2007108009A1 WO2007108009A1 PCT/IN2007/000107 IN2007000107W WO2007108009A1 WO 2007108009 A1 WO2007108009 A1 WO 2007108009A1 IN 2007000107 W IN2007000107 W IN 2007000107W WO 2007108009 A1 WO2007108009 A1 WO 2007108009A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- topiramate
- purification
- purity
- water
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
Definitions
- the present invention relates to a process for purification of Topiramate of formula (I).
- Topiramate is chemically known as 2, 3:4, 5-Bis-O-(1-methylethylidene)-1-O- sulfamoyl-beta-D-fructopyranose or 2, 3:4, 5-Bis-O-(1-methylethylidene)- beta-D- fructopyranose sulfamate, having molecular formula C1 2 H21NO8S and molecular weight 339.36.
- the current pharmaceutical product containing this drug is being sold by Ortho McNeil using the tradename Topamax ® in the form of tablets.
- Topiramate is sulfamate-substituted monosaccharide derivative which are useful in the treatment of epilepsy, obesity, bipolar disorder, neuropathic pain, migraine and smoking cessation.
- Topiramate acts as a carbonate dehydratase inhibitor, sodium channel blocker, AMPA antagonist, GABA agonist and glutamate antagonist.
- Topiramate is first disclosed in US Patent No. 4,513,006 which also discusses its process for preparation. The final product is recrystallized from a mixture of ethyl acetate and hexane. However this process for purification remains silent about purity and yield of Topiramate.
- US Patent No. 5,387,700 which discloses the recrystallization of Topiramate by using ethanol: water mixture as solvent which requires base treatment. This patent also discloses crystallization by using n-hexane which does not give Topiramate with high purity and yield.
- Topiramate Form I obtained by present invention is characterized by its XRD pattern as shown in Fig.1.
- Fig. 1 represnts the powder X-ray diffraction (XRD) pattern of Topiramate Form I.
- Another object of the present invention is to provide a process for the purification of Topiramate which is operationally simple, easy to handle and applicable at an industrial scale.
- Yet another object of the present invention is to provide process for purification of ; Topiramate which comprises purification of Topiramate by treating Topiramate base with mixture of acetone and water.
- present invention relates to a process for the purification of Topiramate comprising a step of treating Topiramate base with a mixture of acetone and water.
- Crude Topiramate as used hereinabove is meant to include Topiramate is any form, or hydrate, solvate or their mixtures, or any state of purity.
- treating refers to suspending, dissolving, washing, mixing, crystallizing or recrystallizing Topiramate in any of the solvent described above.
- Topiramate Form I as prepared according to aspect of present invention is characterized by powder X-ray diffraction peaks at about 9.2, 12.1, 13.0, 15.3, 16.1 , 17.2, 19.9, 20.7, 21.1 , 24.5, 25.8, 29.3 and 32.8 ⁇ 0.2 degree two-theta.
- Topiramate is dissolved in acetone at about 20 0 C to 35 0 C under stirring to obtain a solution. Water is added to said solution drop wise under stirring. The slurry was cooled to about 0 0 C to about 15°C and stirred for about 1 hour to about 4 hours. It is filtered, washed with water and dried to obtain pure crystalline form of Topiramate.
- crude Topiramate is dissolved in acetone at about 20 0 C to 35 0 C under stirring to obtain a solution.
- the said solution is added to chilled water in one lot.
- the slurry is stirred for about 1 hour to about 4 hours at about chilled temperature to ambient temperature. It is filtered, washed with water and dried to obtain pure Topiramate Form.
- purification refers to any method known to a person skilled in the art such as purification from single solvent or combination of solvents by dissolving the compound optionally at elevated temperature and precipitating the compound by cooling the solution or removing solvent from the solution or both. It further includes methods such as solvent/antisolvent or precipitation.
- Topiramate Form I is isolated from reaction mass by conventional isolation procedure such as filtration, centrifugation, washing the wet cake and drying or by evaporation of solvent.
- Topiramate (10g) was dissolved in acetone (20ml) at about 20 0 C to 35 0 C under stirring to obtain a solution. The said solution was added to chilled water (40 ml) in one lot.Topiramate was started to crystallize out. The slurry was stirred for 2 hour at about chilled temperature to ambient temperature. It was filtered, washed with water and dried to obtain pure form of Topiramate (8.4gm), purity of at least 99.5% (HPLC).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Saccharide Compounds (AREA)
- Hematology (AREA)
Abstract
La présente invention concerne un nouveau procédé de préparation de la forme I du topiramate, lequel procédé comprenant la purification du topiramate brut sur la base du traitement de ce-dernier avec un mélange d'acétone et d'eau pour donner le topiramate d'une pureté d'au moins 99,5 %.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN371/MUM/2006 | 2006-03-17 | ||
IN371MU2006 | 2006-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007108009A1 true WO2007108009A1 (fr) | 2007-09-27 |
Family
ID=38325553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2007/000107 WO2007108009A1 (fr) | 2006-03-17 | 2007-03-15 | Procede de purification du topiramate |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007108009A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5387700A (en) * | 1991-09-19 | 1995-02-07 | Mcneilab, Inc. | Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose and (1-methylcyclohexyl)methanol |
WO2004108732A1 (fr) * | 2003-05-12 | 2004-12-16 | Sun Pharmaceutical Industries Limited | PROCEDE DE PREPARATION DE SULFAMATE2,3:4,5-BIS-O(1-METHYLETHYLIDENE)-ss-D-FRUCTOPYRANOSE |
EP1627881A1 (fr) * | 2004-08-19 | 2006-02-22 | Helm AG | Procédé de préparation de topiramate |
-
2007
- 2007-03-15 WO PCT/IN2007/000107 patent/WO2007108009A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5387700A (en) * | 1991-09-19 | 1995-02-07 | Mcneilab, Inc. | Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose and (1-methylcyclohexyl)methanol |
WO2004108732A1 (fr) * | 2003-05-12 | 2004-12-16 | Sun Pharmaceutical Industries Limited | PROCEDE DE PREPARATION DE SULFAMATE2,3:4,5-BIS-O(1-METHYLETHYLIDENE)-ss-D-FRUCTOPYRANOSE |
EP1627881A1 (fr) * | 2004-08-19 | 2006-02-22 | Helm AG | Procédé de préparation de topiramate |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US8889190B2 (en) | 2013-03-13 | 2014-11-18 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US10363224B2 (en) | 2013-03-13 | 2019-07-30 | Upsher-Smith Laboratories, Llc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US9555005B2 (en) | 2013-03-15 | 2017-01-31 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US10172878B2 (en) | 2013-03-15 | 2019-01-08 | Upsher-Smith Laboratories, Llc | Extended-release topiramate capsules |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2125705A2 (fr) | Base de minocycline cristalline et procédés de préparation | |
JP7160946B2 (ja) | (チオ)ニコチンアミドリボフラノシド塩および組成物、製造方法、およびそれらの使用 | |
AU2011334928B2 (en) | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size | |
AU2002241764A1 (en) | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof | |
WO2014041566A2 (fr) | Procédé amélioré de préparation de chlorhydrate de metformine | |
WO2008010231A2 (fr) | Procédé pour la purification de topiramate | |
CN102850418B (zh) | 一种制备高纯度阿扎胞苷的结晶及干燥方法 | |
WO2007108009A1 (fr) | Procede de purification du topiramate | |
JPH08134055A (ja) | 3−o−置換アスコルビン酸の製造方法 | |
JP2018528233A (ja) | インドリン化合物および新規インドリン塩を製造するプロセス | |
EP2341056B1 (fr) | Procédé de cristallisation d érythromycine | |
WO2011015219A1 (fr) | Procédé de purification d'azithromycine par séparation de ses produits de dégradation thermiques et/ou isomères | |
WO2012070066A1 (fr) | Procédé de préparation de taurolidine et de produits intermédiaires de celle-ci | |
WO2020039449A1 (fr) | Procédé amélioré pour la préparation d'acide obéticholique et intermédiaires utilisés dans le procédé | |
CN107151261B (zh) | 一种地红霉素化合物的晶型及其结晶制备方法 | |
WO2000035934A1 (fr) | Intermediaires macrolides pour la preparation de clarithromycine | |
AU2008298402B2 (en) | Method for producing N-methacryloyl-4-cyano-3-trifluoromethylaniline | |
WO2002060873A1 (fr) | Dihydrochlorure d'acide 3-(3-amidinophenyl)-5-[({[1-(1-(-iminoethyl)-4-piperidyl}amino)methyl]benzoique, et procede d'elaboration | |
RU2130942C1 (ru) | Способ получения 3'-азидо-2', 3'-дидезокситимидина | |
US10011626B2 (en) | Method for the purification of decitabine | |
US6008413A (en) | Process for recrystallizing 1,3-bis(aminophenoxy benzene) | |
KR20060110867A (ko) | 독시플루리딘의 제조 방법 | |
US20050228008A1 (en) | Process for obtaining the polymorphic form I of finasteride | |
JPH051053A (ja) | 6−(3−ジメチルアミノプロピオニル)フオルスコリンの新規製造法 | |
JP2000178294A (ja) | ペンタアセチル―β―D―グルコ―スの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07736567 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07736567 Country of ref document: EP Kind code of ref document: A1 |